TopoTarget and NeuroSearch enter development and licensing agreement  

2005.09.01
The Danish based biotech companies TopoTarget and NeuroSearch have signed a development and licensing agreement concerning NeuroSearch compound NSD-551 for the treatment of cancer

The Danish based biotech companies TopoTarget and NeuroSearch have signed a development and licensing agreement concerning NeuroSearch compound NSD-551 for the treatment of cancer. TopoTarget will test the compound in its preclinical models, and if results are promising clinical development will be initiated. The two companies will share future potential revenues from commercialisation of the product.

NSD-551 activates an ion channel which is important for transport of anti-cancer drugs into brain tumours, and thus has the potential to enhance the effect of a number of anti-cancer drugs. The news was reported by BiotechDenmark online and on the TopoTarget website.

TopoTarget was established in 2000 and has grown both organically and through acquisitions. In 2002, the company acquired the UK cell cycle company Profilix, and in 2005 the German company G2M Cancer Drugs. TopoTarget is headquartered in Copenhagen and has operations in Oxford UK, and in Frankfurt and Karlsruhe, Germany.

NeuroSearch is listed on the Copenhagen Stock Exchange. The company has a wide research and development portfolio including compounds for the treatment of Alzheimer's disease, anxiety disorders, cancer, depression, epilepsy, pain and Parkinson's disease.

Link > TopoTarget 

Link > NeuroSearch 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×